Technical Analysis for STML - Stemline Therapeutics, Inc.

Grade Last Price % Change Price Change
grade A 19.65 1.29% 0.25
STML closed up 1.29 percent on Thursday, May 24, 2018, on 33 percent of normal volume.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical STML trend table...

Date Alert Name Type % Chg
May 24 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
May 24 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
May 24 Inside Day Range Contraction 0.00%
May 23 Bearish Engulfing Bearish 1.29%
May 23 Outside Day Range Expansion 1.29%
May 22 New 52 Week Closing High Bullish -0.51%
May 22 180 Bullish Setup Bullish Swing Setup -0.51%
May 22 Overbought Stochastic Strength -0.51%
May 18 1,2,3 Pullback Bullish Bullish Swing Setup 1.03%
May 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.03%

Older signals for STML ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing proprietary therapeutics that target cancer stem cells (CSCs) and tumor bulk. It develops StemScreen platform technology consisting of StemScreen-1 and StemScreen-2 for the identification of novel CSC-directed compounds. The company is developing SL-401, a biologic-drug conjugate, which has completed Phase I/II clinical trial for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine that has completed two Phase I/II clinical trials for pediatric and adult high-grade gliomas. Its products under preclinical stage include SL-301, a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bulk of multiple cancer types; SL-101, a mAb-based compound that targets CD123; SL-201, a small molecule active against certain hematologic and solid tumor types; and SL-601, mAb-based compound that targets a cell surface marker on bladder CSCs. The company also in-licensed intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened, and Patched. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
Is STML a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 20.2
52 Week Low 7.3
Average Volume 297,746
200-Day Moving Average 14.1473
50-Day Moving Average 17.034
20-Day Moving Average 18.7275
10-Day Moving Average 19.4
Average True Range 0.7034
ADX 35.1
+DI 29.04
-DI 11.37
Chandelier Exit (Long, 3 ATRs ) 18.0898
Chandelier Exit (Short, 3 ATRs ) 18.9102
Upper Bollinger Band 20.2948
Lower Bollinger Band 17.1602
Percent B (%b) 0.79
BandWidth 16.737952
MACD Line 0.6937
MACD Signal Line 0.6836
MACD Histogram 0.0101
Fundamentals Value
Market Cap 460.88 Million
Num Shares 23.5 Million
EPS -2.47
Price-to-Earnings (P/E) Ratio -7.96
Price-to-Sales 202.21
Price-to-Book 3.03
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.48
Resistance 3 (R3) 20.43 20.12 20.34
Resistance 2 (R2) 20.12 19.91 20.14 20.29
Resistance 1 (R1) 19.88 19.78 20.00 19.93 20.25
Pivot Point 19.57 19.57 19.63 19.59 19.57
Support 1 (S1) 19.33 19.36 19.45 19.38 19.05
Support 2 (S2) 19.02 19.23 19.04 19.01
Support 3 (S3) 18.78 19.02 18.96
Support 4 (S4) 18.83